Ribić Rosana, Meštrović Tomislav, Neuberg Marijana, Kozina Goran
1Research and Development Department, Tesla Ltd. 42244 Klenovnik, Croatia.
2Clinical Microbiology and Parasitology Unit Polyclinic "Dr. Zora Profozić" 10000 Zagreb, Croatia.
Acta Pharm. 2018 Mar 1;68(1):1-18. doi: 10.2478/acph-2018-0004.
Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) are among the most common infectious diseases in humans. Due to their frequent occurrence in the community and nosocomial settings, as well as the development of resistance to the commonly prescribed antimicrobial agents, an enormous financial burden is placed on healthcare systems around the world. Therefore, novel approaches to the prevention and treatment of UTIs are needed. Although UPEC may harbour a plethora of virulence factors, type I fimbriae and P pili are two of the most studied adhesive organelles, since the attachment to host cells in the urinary tract is a crucial step towards infection. Design of receptor analogues that competitively bind to UPEC surface adhesins placed at the top of pili organelles led to the development of anti-adhesive drugs that are increasingly recognized as important and promising alternatives to antibiotic treatment of UTIs.
由尿路致病性大肠杆菌（UPEC）引起的尿路感染（UTIs）是人类最常见的传染病之一。由于它们在社区和医院环境中频繁发生，以及对常用抗菌药物产生耐药性，给世界各地的医疗系统带来了巨大的经济负担。因此，需要新的方法来预防和治疗尿路感染。尽管UPEC可能含有大量毒力因子，但I型菌毛和P菌毛是研究最多的两种粘附细胞器，因为在尿路中与宿主细胞的附着是感染的关键步骤。设计能与位于菌毛细胞器顶端的UPEC表面粘附素竞争性结合的受体类似物，导致了抗粘附药物的开发，这些药物越来越被认为是治疗尿路感染的抗生素的重要且有前景的替代品。
